<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: Lilly Investor Call Over Byetta Causing Apprehension</title>
	<atom:link href="http://www.pharmalot.com/2008/08/lilly-investor-call-over-byetta-causing-apprehension/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2008/08/lilly-investor-call-over-byetta-causing-apprehension/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 21:46:02 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: Ed Silverman</title>
		<link>http://www.pharmalot.com/2008/08/lilly-investor-call-over-byetta-causing-apprehension/#comment-370290</link>
		<dc:creator>Ed Silverman</dc:creator>
		<pubDate>Tue, 26 Aug 2008 17:57:45 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=15177#comment-370290</guid>
		<description>Hi Terry,

I am 'my reporter,' and I don't claim to have every statistic at my fingertips, nor did I scour the universe for the particular datapoint that you cited. That said, I appreciate the information, assuming it is correct.

Nonetheless, this post simply reports what a Wall Street analyst wrote to her clients this morning about the issue confronting Lilly and Amylin, and which has captured the attention of the FDA. The FDA, in fact, has been monitoring this side effect and, presumably, they are aware of the statistic you cited.

I'm sorry for any confusion, but I'm not sure why you're taking me to task.

Regards
ed</description>
		<content:encoded><![CDATA[<p>Hi Terry,</p>
<p>I am &#8216;my reporter,&#8217; and I don&#8217;t claim to have every statistic at my fingertips, nor did I scour the universe for the particular datapoint that you cited. That said, I appreciate the information, assuming it is correct.</p>
<p>Nonetheless, this post simply reports what a Wall Street analyst wrote to her clients this morning about the issue confronting Lilly and Amylin, and which has captured the attention of the FDA. The FDA, in fact, has been monitoring this side effect and, presumably, they are aware of the statistic you cited.</p>
<p>I&#8217;m sorry for any confusion, but I&#8217;m not sure why you&#8217;re taking me to task.</p>
<p>Regards<br />
ed</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Terry Moore</title>
		<link>http://www.pharmalot.com/2008/08/lilly-investor-call-over-byetta-causing-apprehension/#comment-370283</link>
		<dc:creator>Terry Moore</dc:creator>
		<pubDate>Tue, 26 Aug 2008 17:42:02 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=15177#comment-370283</guid>
		<description>Does your reporter not know that pancreatitis is around 17/100000 in the general population and 3/100000 for those using Byetta? If not,he should try a little research.</description>
		<content:encoded><![CDATA[<p>Does your reporter not know that pancreatitis is around 17/100000 in the general population and 3/100000 for those using Byetta? If not,he should try a little research.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.150 seconds -->

